Therapeutic combination comprising a pulmonary surfactant and a steroid for the treatment of evolving bpd

Abstract

Administering a pulmonary surfactant and a corticosteroid is effective for the treatment of evolving bronchopulmonary dysplasia (BPD) in preterm neonates.

1 . A composition, comprising:
 (a) at least one pulmonary surfactant; and   (b) budesonide,   wherein said budesonide is present in an amount sufficient to deliver a dose of 0.1 to 1.5 mg/kg to a preterm neonate.   
     
     
         2 . A composition according to  claim 1 , which comprises budesonide in an amount sufficient to deliver a dose of 0.2 to 1.0 mg/kg to a preterm neonate. 
     
     
         3 . A composition according to  claim 1 , which comprises budesonide in an amount sufficient to deliver a dose of 0.1 to 0.5 mg/kg to a preterm neonate. 
     
     
         4 . A composition according to  claim 1 , which comprises budesonide in an amount sufficient to deliver a dose of 0.5 to 1.0 mg/kg to a preterm neonate. 
     
     
         5 . A composition according to  claim 1 , which comprises said at least one pulmonary surfactant in an amount sufficient to deliver a dose of 100 to 200 mg/kg a preterm neonate. 
     
     
         6 . A composition according to  claim 1 , which comprises poractant alfa. 
     
     
         7 . A composition according to  claim 1 , which is in a form of an aqueous suspension comprising a pharmaceutically acceptable carrier. 
     
     
         8 . A composition, comprising:
 (a) 20 to 100 mg/ml of at least one pulmonary surfactant; and   (b) 0.05 to 0.5 mg/ml of budesonide.   
     
     
         9 - 25  (canceled)